Hubungan Terapi Kombinasi Mood Stabilizer dan Antipsikotik dengan Kemampuan Fungsional Pasien Gangguan Afektif Bipolar di Rumah Sakit Jiwa Grhasia Yogyakarta

Relationship between Mood Stabilizer and Antipsychotic Combination Therapy with Functional Ability of Bipolar Affective Disorder Patients at Grhasia Mental Hospital Yogyakarta

  • Nadia Utami Noor Universitas Ahmad Dahlan
  • Dyah Aryani Perwitasari Universitas Ahmad Dahlan Yogyakarta
  • Sawitri Sawitri Rumah Sakit Jiwa Grhasia Yogyakarta
Keywords: Bipolar, functional abilities, mood stabilizer, antipsychotics

Abstract

Bipolar disorder is a mental illness that can affect the functional abilities of the patients. It is persistent even in a euthymic condition. There have been number of studies on the effectiveness of mood stabilizer and antipsychotic therapy in bipolar disorder, but there is still few studies related to the effect of the combination therapy of mood stabilizer and antipsychotics on bipolar patient’s functional ability. The objectives of this study is to determine the associatioin of valproate and lithium combined with antipsychotics on functional ability of bipolar disorder patients at Grhasia Mental Hospital Yogyakarta. The study design was cohort retrospective. The data was collected from medical record. The subjects were patients who were hospitalized and undergone therapy combination mood stabilizer and antipsychotics in January-December 2018. Total of 46 patients, 38 received valproate + antipsychotic and 8 patients received lithium + antipsychotic. There was no significant association between the combination therapy group on the patient’s functional abilities [ Odds Ratio (OR) = 1,71; 95% Confidence Interval (CI): 0,37-7,95 ; p = 0,963].

References

[1] Kemenkes RI, Pedoman Nasional Pelayanan Kedokteran Jiwa. Jakarta: Kemenkes RI, 2015.
[2] T. Vos et al., “Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013,” Lancet, vol. 386, no. 9995, pp. 743–800, 2015.
[3] Kemenkes RI, HASIL UTAMA RISKESDAS 2018. Jakarta: Balitbangkes, 2018.
[4] P. B. Mitchell, T. Slade, and G. Andrews, “Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey,” Psychol. Med., vol. 34, no. 5, pp. 777–785, 2004.
[5] Soumya P Thomas, A. Nisha, and P. J. Varghese, “Disability and quality of life of subjects with bipolar affective disorder in remission,” Indian J. Psychol. Med., vol. 38, no. 4, pp. 336–340, 2016.
[6] Lambert PA, C. G, B. S, and C. S, “Neuropsychotropic action of a new anti-epileptic agent: depamide,” Ann Med Psychol, vol. 124, pp. 707–710, 1966.
[7] K. Macritchie et al., “Valproate for acute mood episodes in bipolar disorder,” Cochrane Database Syst. Rev., vol. 2003, no. 1, 2003.
[8] L. A. Smith, V. Cornelius, A. Warnock, M. J. Tacchi, and D. Taylor, “Acute bipolar mania: A systematic review and meta-analysis of co-therapy vs. monotherapy,” Acta Psychiatr. Scand., vol. 115, no. 1, pp. 12–20, 2007.
[9] American Psychriatric Association, “Practice guideline for the treatment of patients with bipolar disorder (revision),” Am. J. Psychiatry, vol. 159, no. 4, pp. 1–50, 2002.
[10] T. Miura et al., “Comparative effi cacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder : a systematic review and network meta-analysis,” The Lancet Psychiatry, vol. 1, no. 5, pp. 351–359, 2014.
[11] M. G. Kang et al., “Lithium vs valproate in the maintenance treatment of bipolar I disorder : A post- hoc analysis of a randomized double- blind placebo-controlled trial,” Aust. New Zeal. J. Psychiatry, vol. 00, no. 0, pp. 1–10, 2019.
[12] R. R. Kavitha, S. Kamalam, and R. P. Rajkumar, “Functional ability of clients with bipolar disorders in tertiary hospital, Puducherry,” Int. J. Community Based Nurs. Midwifery, vol. 6, no. 1, pp. 21–28, 2018.
[13] M. Chen, H. M. Fitzgerald, J. J. Madera, and M. Tohen, “Functional outcome assessment in bipolar disorder: A systematic literature review,” Bipolar Disord., vol. 21, no. 3, pp. 194–214, 2019.
[14] American Psychriatric Association, Diagnostic and Statistical Manual of Mental Disorder (DSM-IV-TR), Fourth Edi. Washington DC: American Psychiatric Association, 2000.
[15] I. M. Aas, “Guidelines for rating Global Assessment of Functioning (GAF),” Ann. Gen. Psychiatry, vol. 10, no. 1, p. 2, 2011.
[16] L. M. Arnold, “Gender differences in bipolar disorder,” Psychiatr. Clin. North Am., vol. 26, no. 3, pp. 595–620, 2003.
[17] I. M. Johan, Evaluasi Kerasionalan dan Kuantitas Penggunaan Kombinasi Obat Mood Stabilizer dan Antipsikotik pada Pasien Bipolar di Rumah Sakit Jiwa Grhasia Yogyakarta, Skripsi. Yogyakarta: Fakultas Farmasi Universitas Ahmad Dahlan, 2017.
[18] A. Cipriani, K. Reid, A. H. Young, K. Macritchie, and J. Geddes, “Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder,” Cochrane Database Syst. Rev., vol. 2013, no. 10, 2013.
[19] W. A. Nolen, “More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder : should lithium ( again ) be recommended as the single preferred first-line treatment ?,” Int. J. Bipolar Disord., vol. 3, no. 1, pp. 1–3, 2015.
[20] C. L. Bowden et al., “Efficacy of valproate versus lithium in mania or mixed mania : a randomized , open 12-week trial,” Int. Clin. Psychopharmacol., vol. 25, no. 2, pp. 60–67, 2010.
[21] S. W. Ahn et al., “Long ‑ term response to mood stabilizer treatment and its clinical correlates in patients with bipolar disorders : a retrospective observational study,” Int. J. Bipolar Disord., vol. 5, no. 24, pp. 1–9, 2017.
[22] R. F. Mcknight, M. Adida, K. Budge, S. Stockton, G. M. Goodwin, and J. R. Geddes, “Lithium toxicity profi le : a systematic review and meta-analysis,” Lancet, vol. 379, no. 9817, pp. 721–728, 2012.
[23] G. Ayano, “Bipolar Disorder : Open Access Bipolar Disorders and Valproate : Pharmacokinetics , Pharmacodynamics , Therapeutic Effects and Indications of Valproate : Review of Articles,” Bipolar Disord., vol. 2, no. 2, pp. 1–5, 2016.
Published
2021-10-31
How to Cite
Noor, N. U., Perwitasari, D. A., & Sawitri, S. (2021). Hubungan Terapi Kombinasi Mood Stabilizer dan Antipsikotik dengan Kemampuan Fungsional Pasien Gangguan Afektif Bipolar di Rumah Sakit Jiwa Grhasia Yogyakarta . Jurnal Sains Dan Kesehatan, 3(5), 633-638. https://doi.org/10.25026/jsk.v3i5.536